SCHEMBL15935398

SCHEMBL15935398

Cc1ccn(-c2cnn(C)c(=O)c2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.43
RAB9A P51151 3/20 0.41
MAPT P10636 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
AVPR2 P30518 5/20 0.40
OXTR P30559 3/20 0.40
AVPR1A P37288 3/20 0.40
NPC1 O15118 2/20 0.39
ATM Q13315 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TDO2 P48775 1/20 0.36
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
PTGS1 P23219 1/20 0.34
HDAC4 P56524 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15923948 0.83 PTGS1 (0.33) L3MBTL1MEN1KMT2APTGS1
SCHEMBL22041234 0.73 HTT (0.44) HTTRAB9AMAPTKDM4EALDH1A1
SCHEMBL22796241 0.68 HTT (0.50) HTTRAB9AMAPTKDM4EALDH1A1
SCHEMBL982486 0.68 CYP3A4 (0.46) MAPTALDH1A1GAAATM
SCHEMBL28870075 0.67 MAPT (0.52) HTTRAB9AMAPTKDM4EALDH1A1
SCHEMBL14412226 0.67 RAB9A (0.59) HTTRAB9AMAPTKDM4EALDH1A1
SCHEMBL2690822 0.67 ELOVL1 (0.46) HTTRAB9AMAPTKDM4EALDH1A1
SCHEMBL17158243 0.67 KAT6A (0.46) HTTRAB9AMAPTKDM4EALDH1A1
SCHEMBL8404399 0.67
SCHEMBL23176111 0.66 HTT (0.44) HTTRAB9AMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9708308-B2 Factor IXa inhibitors MERCK SHARP DOHME CORP. (US) 2017-07-18 US disclosed
US-20150322056-A1 Factor IXa Inhibitors MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-11-12 US disclosed
WO-2014120346-A1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322056-A1 Factor IXa Inhibitors F9, F12, F8 HTT 1935/4885RAB9A 556/4885MAPT 4751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.